EQA PROGRAMME CATALOGUE
77Pages

{{requestButtons}}

Catalog excerpts

EQA PROGRAMME CATALOGUE - 2

An Introduction to the QCMD EQA Schemes 5 Blood Borne Virus 6 Central Nervous System 6 Immunocompromised Associated Diseases 9 Sexually Transmitted Infections 11 Transplant Associated Diseases 11 Cytomegalovirus Dried Blood Spots 16 Cytomegalovirus Whole Blood 16 Epstein-Barr virus Whole Blood 19 Herpes simplex virus 1& 2 25 Herpes simplex virus Drug Resistance 25 HIV-1 Drug Resistance (Integrase) 27 Human herpes virus 6 28

Open the catalog to page 2
EQA PROGRAMME CATALOGUE - 3

Human Papillomavirus (PreservCyt) 29 Influenza Haemagglutinin Typing 30 Respiratory syncytial virus 34 West Nile virus 35 Borrelia burgdorferi spp. (Lyme Disease) 38 Chlamydia trachomatis and Neisseria gonorrhoeae 39 Diarrheagenic Escherichia coli 41 Extended Spectrum ^-lactamase and Carbapenemase 41 Methicillin Resistant Staphylococcus aureus 43 Methicillin Resistant Staphylococcus aureus Typing 44 (epidemiology and outbreak studies) Mycobacterium tuberculosis 44 Mycoplasma spp. (cell contamination) 45 Vancomycin Resistant Enterococci 47 Pneumocystis...

Open the catalog to page 3
EQA PROGRAMME CATALOGUE - 4

Contents Multiple Pathogen EQA Bacterial Gastroenteritis MALDI-TOF Parasitic Gastroenteritis Respiratory I Respiratory II Respiratory III Sexually Transmitted Infections I Sexually Transmitted Infections II Viral Gastroenteritis EQA Pilot Studies CNSI (Viral) CNSII (Non-viral) Human Papillomavirus (Surepath) Immunocompromised Mycoplasma genitalium Neonatal / Newborn infections Sepsis Torque teno virus Transplantation (viral) Trichomonas vaginalis New Molecular EQA Pilot Studies for 2019 Arthropod-borne viruses Atypical mycobacterium Mycobacterium tuberculosis Drug Resistance Yellow fever...

Open the catalog to page 4
EQA PROGRAMME CATALOGUE - 5

An Introduction to the QCMD EQA Schemes The aim of QCMD's External Quality Assessment (EQA) programmes are to help monitor and improve laboratory quality by assessing a laboratory's use of molecular diagnostic technologies within the routine clinical setting. The EQA schemes are both educational and regulatory in application and support continuous quality improvement, as well as assist laboratory accreditation / certification to ISO15189 or equivalent. Who can participate? The QCMD EQA programmes are open to any clinical laboratory conducting molecular based tests for the routine diagnosis...

Open the catalog to page 5
EQA PROGRAMME CATALOGUE - 6

EQA GroupsBloodborne Virus The Bloodborne Virus (BBV) group of QCMD External Quality Assessment (EQA) programmes consists of pathogens that are classically detected directly from the blood. This includes human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) B19 virus (B19) and more recently hepatitis A virus (HAV), hepatitis E virus (HEV) and hepatitis D virus (HDV). To compliment the detection and viral load determination programme above a range of genotyping and drug resistance BBV EQA programmes are available. For the drug resistance BBV EQA programmes...

Open the catalog to page 6
EQA PROGRAMME CATALOGUE - 7

EQA Groups Congenital Infections The term congenital infection is used to describe those infections transmitted from mother to child either during pregnancy (Transplacental infection) or immediately after childbirth. They can be caused by viruses, bacteria and on occasion parasites. The ability of a particular pathogen to cross the placenta and infect the foetus /embryo is dependent on many factors including the mother’s immune status. Primary infections during pregnancy can result in spontaneous abortion or major developmental disorders if undetected and left untreated. Cytomegalovirus...

Open the catalog to page 7
EQA PROGRAMME CATALOGUE - 8

EQA Groups Exotic/Emerging Diseases A complex relationship exists between pathogen genetics, host and the environment. As a result, predicting the future emergence of exotic diseases is difficult. However, globalisation coupled with rapid increases in human populations over the last 50 years has played an important role. Local environmental changes such as deforestation due to urbanisation bring humans into closer contact with potential new pathogen vectors. These factors disturb the subtle balance between pathogen, host and the environment and create the opportunity for the emergence of...

Open the catalog to page 8
EQA PROGRAMME CATALOGUE - 9

Immunocompromised Associated Diseases The treatment and management of patients with compromised immune systems has seen important developments in recent years with, for example, the introduction of novel multi-drug treatment regimes. As a result, the healthcare and management of immunocompromised patients has greatly improved. However, pathogen infection or viral reactivation remain significant contributors to morbidity and mortality in these patients. A number of opportunistic parasitic, fungal and viral pathogens are of concern in the management of immunocompromised patients due to both...

Open the catalog to page 9
EQA PROGRAMME CATALOGUE - 10

Respiratory Diseases Respiratory tract infections (RTIs) are common conditions, experienced by most adults and children each year. They can affect both the upper and lower respiratory tract and range from the common cold to viral and bacterial pneumonia. For the young, the elderly and the immune compromised, RTIs can be a significant health threat if not managed effectively. RTIs can be caused by a large number of bacterial, viral and fungal pathogens which have nearly indistinguishable physiological symptoms. This can increase the chances of undiagnosed or misdiagnosed infections leading...

Open the catalog to page 10
EQA PROGRAMME CATALOGUE - 11

Sexually transmitted infections (STIs) remain a major public health concern throughout the world with some infections reaching epidemic proportions in sexually active groups. As a result, a number of WHO and UN global strategies have been initiated in an attempt to control the spread of STIs. STIs are the main preventable cause of infertility, particularly in women. However, some STIs remain asymptomatic before leading to serious reproductive complications and congenital infections, therefore appropriate diagnosis and treatment is essential. Molecular diagnostic assays allow the accurate...

Open the catalog to page 11
EQA PROGRAMME CATALOGUE - 12

Advances in the treatment and management of patient infection have seen important developments in recent years. In particular the introduction of novel antiviral drug therapies has improved the medium and long-term prospects of infected patients. However, the development of drug resistant pathogens is an increasing complication and remains a significant factor in the treatment of these patient groups. The use of genotyping and sequencing technologies has allowed accurate pathogen assessment and monitoring of patient samples over time. This allows early and accurate determination of pathogen...

Open the catalog to page 12

All AB Analitica catalogs and technical brochures

  1. Catalogue 2023

    36 Pages